This press release replaces the release issued today at 9:15am EDT.

Revolutionary AI-driven cheek swab test poised to transform early cancer detection with continuously improving accuracy. 

Revealia™: A Breakthrough in Cancer Detection through Advanced AI and Machine Learning

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force

Up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy

• Orders from Distributors in Germany, Switzerland and Austria will be fulfilled as soon as possible

• Germany and the United Kingdom are two of the largest fitness markets globally

• European Union compliance standards are some of the most stringent

• Third quarter revenue will be significantly higher than previous quarters

SPIKEVAX^® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians this fall and winter season.

Moderna will promptly begin delivery of updated COVID-19 vaccines to the Public Health Agency of Canada, so there is robust supply available in time for provincial and territorial vaccination campaigns.

Ainos Plans To Conduct the Study at National Taiwan University Hospital, a Premier Taiwanese Medical Center for HIV Management

The U.S. FDA Have Granted Orphan Drug Designation (ODD) for the Company's VELDONA^® Low-Dose Oral Interferon Formulation as a Potential Treatment for Oral Warts in HIV-Positive Patients

Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types

Prolonged stable disease lasting >11 months demonstrated in Breast Cancer Patient

Favorable Pharmacokinetics, Safety and Tolerability Observed

Data Presented at the European Society of Medical Oncology on September 14, 2024